Wells Fargo Rates Travere Therapeutics (TVTX) buy

Wells Fargo reiterates its buy rating on Travere Therapeutics with a target price of $65, signaling confidence in the company's future, a 20.06% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:11 PM EDT · Updated Jun 18, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wells Fargo rated Travere Therapeutics, Inc. ($TVTX) "buy" with a $65 price target on June 12, 2026.

Since the rating, $TVTX is up 5.9% after 1 week, up 8.2% after 1 month and down 4.7% to date (from the $52.04 close on Jun 12, 2026).

TVTX Travere Therapeutics, Inc.

$49.60 +25.51% year to date

Daily close · Oct 16, 2026

Key Points

Wells Fargo reiterated its buy rating on Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 12, 2026, with a price target of $65.00.
Currently, Travere's stock trades at $54.14, which is below the new target and suggests potential upside.
The average price target among analysts for Travere is $74.21, indicating strong support for the stock's future performance.

Get $TVTX trade alerts by text

We text you when insiders, Congress or big funds trade $TVTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Travere Therapeutics, Inc. alert may contain errors. Disclosures

Wells Fargo's Continued Support

Wells Fargo reiterated its buy rating on Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 12, 2026, maintaining a price target of $65. This move reflects the firm’s confidence in Travere's growth potential within the healthcare sector, particularly as it develops treatments for rare kidney and metabolic diseases.

Analysts Set New Price Targets

Wells Fargo's action comes amid a generally positive outlook from other analysts. For instance, Guggenheim maintains a buy rating with a price target of $89, up from $75. Wedbush also reiterated its outperform rating with a target of $76. On September 22, HC Wainwright & Co. reaffirmed its buy rating with a target of $67. The consensus among 14 analysts suggests a strong buy recommendation, with an average price target of $74.21, indicating solid support for the stock's future performance.

Stock Performance and Market Context

Travere's shares are currently trading at $54.14, which is below the new target set by Wells Fargo. The stock has fluctuated between a 52-week low of $22.06 and a high of $68.73. This price range highlights the potential for growth, especially as the company's pipeline continues to develop. The stock’s performance is noteworthy, given its recent trading activity compared to its 50-day moving average of $61.71.

12-month forecast

$TVTX price target

Travere Therapeutics, Inc. daily closes and this analyst's $65 target. Not advice.

Recent Earnings

Travere Therapeutics reported revenue of approximately $591.3 million, showing a growth rate of 48.2%. However, the company is still operating at a loss, with an EPS of -0.73. Investors will be looking forward to the next earnings report, scheduled for October 29, 2026, for more insights into the company's financial health and operational progress.

What Travere Therapeutics, Inc. Does

Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, CA, focused on developing therapies for rare kidney and metabolic diseases. Its key products include FILSPARI, an oral medication for IgA nephropathy, and Thiola for cystinuria. The company's innovative approach positions it well in the healthcare sector, driving interest from analysts and investors alike.

What's Ahead for Travere Therapeutics, Inc.

As Travere prepares for its upcoming earnings report, analysts will continue to monitor its performance and any developments in its drug pipeline. The reaffirmation of buy ratings from Wells Fargo and other firms underscores a positive sentiment in the market. Investors should keep an eye on future filings and the evolving landscape of the biotechnology sector.